Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Jayna J Mistry; Charlotte Hellmich; Amelia Lambert; Jamie A Moore; Aisha Jibril; Angela Collins; Kristian M Bowles; Stuart A Rushworth

doi:10.1186/s40364-021-00291-y

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Jayna J Mistry, Charlotte Hellmich, Amelia Lambert, Jamie A Moore, Aisha Jibril, Angela Collins, Kristian M Bowles, Stuart A Rushworth

Research output: Contribution to journal › Letter › peer-review

5 Citations (SciVal)

17 Downloads (Pure)

Abstract

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

Original language	English
Article number	35
Journal	Biomarker Research
Volume	9
Issue number	1
DOIs	https://doi.org/10.1186/s40364-021-00291-y
Publication status	Published - 13 May 2021

Access to Document

10.1186/s40364-021-00291-yLicence: CC BY

Published_VersionAccepted author manuscript, 2.3 MBLicence: CC BY

https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-021-00291-yLicence: CC BY

Cite this

@article{361159e4275f43cfbd5fd85fe0ecb1f3,

title = "Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia",

abstract = "Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.",

author = "Mistry, {Jayna J} and Charlotte Hellmich and Amelia Lambert and Moore, {Jamie A} and Aisha Jibril and Angela Collins and Bowles, {Kristian M} and Rushworth, {Stuart A}",

year = "2021",

month = may,

day = "13",

doi = "10.1186/s40364-021-00291-y",

language = "English",

volume = "9",

journal = "Biomarker Research",

issn = "2050-7771",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

AU - Mistry, Jayna J

AU - Hellmich, Charlotte

AU - Lambert, Amelia

AU - Moore, Jamie A

AU - Jibril, Aisha

AU - Collins, Angela

AU - Bowles, Kristian M

AU - Rushworth, Stuart A

PY - 2021/5/13

Y1 - 2021/5/13

N2 - Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

AB - Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

UR - http://www.scopus.com/inward/record.url?scp=85105869895&partnerID=8YFLogxK

U2 - 10.1186/s40364-021-00291-y

DO - 10.1186/s40364-021-00291-y

M3 - Letter

SN - 2050-7771

VL - 9

JO - Biomarker Research

JF - Biomarker Research

IS - 1

M1 - 35

ER -

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Abstract

Access to Document

Other files and links

Cite this